Table 3. Demographics and initial ocular characteristics of treatment-switched patients.
| BCVA responders | BCVA non-responders | Fundus responders | Fundus non-responders | |
|---|---|---|---|---|
| (60 eyes) | (11 eyes) | (65 eyes) | (6 eyes) | |
| Ratio to switched patients (%) | 84.5 | 15.5 | 91.5 | 8.5 |
| Age, mean ± SD | 71.8 ± 8.7 | 73.4 ± 7.7 | 72.2 ± 8.5 | 69.3 ± 8.3 |
| Male, (eyes [%[) | 44 (73.3) | 7 (63.6) | 46 (70.8) | 5 (83.3) |
| AMD type | ||||
| Typical AMD | 26 | 6 | 29 | 3 |
| PCV | 32 | 5 | 34 | 3 |
| RAP | 2 | 0 | 2 | 0 |
| BCVA, mean ± SD (logMAR) | 0.39 ± 0.39 | 0.48 ± 0.30 | 0.42 ± 0.39 | 0.18 ± 0.21 |
| CRT, mean ± SD (μm) | 379 ± 218 | 446 ± 195 | 393 ± 216 | 346 ± 212 |
| GLD, mean ± SD (μm) | 4111 ± 2341 | 5131 ± 3344 | 4385 ± 2556 | 3021 ± 1831 |
| CCT, mean ± SD (μm) | 185 ± 55 | 191 ± 60 | 190 ± 48 | 186 ± 56 |
| Type 1 CNV (eyes [%]) | 36 (60.0) | 5 (45.5) | 38 (58.4) | 3 (50.0) |
AMD, age-related macular degeneration; PCV, polypoidal choroidal vasculopathy; RAP, retinal angiomatous proliferation; BCVA, best corrected visual acuity; CNV, choroidal neovascularization; CRT, central retinal thickness; GLD, greatest linear dimension; CCT, central choroidal thickness.